322 related articles for article (PubMed ID: 34672090)
41. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
42. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
Solsky I; Chen J; Rebbeck TR
Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
[TBL] [Abstract][Full Text] [Related]
43. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
44. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
45. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
46. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Kotsopoulos J; Huzarski T; Gronwald J; Moller P; Lynch HT; Neuhausen SL; Senter L; Demsky R; Foulkes WD; Eng C; Karlan B; Tung N; Singer CF; Sun P; Lubinski J; Narod SA
Breast Cancer Res Treat; 2016 Jan; 155(2):365-73. PubMed ID: 26780555
[TBL] [Abstract][Full Text] [Related]
47. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
48. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Finch A; Evans G; Narod SA
Womens Health (Lond); 2012 Sep; 8(5):543-55. PubMed ID: 22934728
[TBL] [Abstract][Full Text] [Related]
49. Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.
Feng Z; Zuo K; Ju X; Chen X; Yang W; Wen H; Yu L; Wu X
J Ovarian Res; 2023 Jun; 16(1):125. PubMed ID: 37386498
[TBL] [Abstract][Full Text] [Related]
50. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
51. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A; Vecchiola A; Aguirre B; Villaseca P
Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
[TBL] [Abstract][Full Text] [Related]
52. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
53. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
54. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
55. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
[TBL] [Abstract][Full Text] [Related]
56. Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer.
Nappi RE; Cassani C; Rossi M; Zanellini F; Spinillo A
Minerva Ginecol; 2016 Oct; 68(5):602-12. PubMed ID: 26928421
[TBL] [Abstract][Full Text] [Related]
57. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
Finch A; Narod SA
Maturitas; 2011 Nov; 70(3):261-5. PubMed ID: 21893388
[TBL] [Abstract][Full Text] [Related]
58. Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
Nomura H; Sekine M; Yokoyama S; Arai M; Enomoto T; Takeshima N; Nakamura S
Int J Clin Oncol; 2019 Sep; 24(9):1105-1110. PubMed ID: 31055694
[TBL] [Abstract][Full Text] [Related]
59. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
Schwartz ZP; Li AJ; Walsh CS; Rimel BJ; Alvarado MM; Lentz SE; Cass I
Gynecol Oncol; 2023 Jun; 173():1-7. PubMed ID: 37030072
[TBL] [Abstract][Full Text] [Related]
60. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Guidozzi F
Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]